Please provide your email address to receive an email when new articles are posted on . Three years ago, tragedy struck my family with the loss of my brother due to metastatic lung cancer. My brother ...
Credit: Shutterstock. Ryzumvi is a preservation-free eye drop formulation of phentolamine mesylate, an alpha adrenergic blocker. The Food and Drug Administration (FDA) has approved Ryzumvi™ ...
Please provide your email address to receive an email when new articles are posted on . In a second phase 3 registration trial, Nyxol helped reverse pharmacologically induced mydriasis at 90 minutes, ...
The FDA has approved phentolamine ophthalmic solution (Ryzumvi) 0.75% for treatment-induced mydriasis, Viatris and Ocuphire Pharma announced. The approval stipulates use of the eye drops to manage ...
NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device ...
To describe two cases of stereotyped, intermittent, neurologically isolated, unilateral mydriasis in patients with a history of acquired internal carotid artery (ICA) occlusive disease on the ...
A 3-year-old girl with an unremarkable medical history suddenly developed dilated pupils and trouble walking, according to a case report in JAMA Ophthalmology. The child was brought in to the ...
Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Mydriasis pipeline constitutes 3+ key companies continuously working towards developing 3+ Mydriasis treatment therapies, ...
Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Mydriasis - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The 'Mydriasis ...
Purpose To assess the effect of diagnostic mydriasis with 1% cyclopentolate on the intraocular pressure (IOP) of patients attending glaucoma, medical retina and cataract clinics. Methods Levels of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results